527.95 -7.30 (-1.36%)
- 1D
- 5D
- 1M
- 6M
- 1Y
- 5Y
Price Range
Today’s Low
527.3
Today’s High
535.45
52 Week Low
525.3
52 Week High
792.3
528.30 -6.85 (-1.28%)
- 1D
- 5D
- 1M
- 6M
- 1Y
- 5Y
Price Range
Today’s Low
527
Today’s High
536
52 Week Low
525.25
52 Week High
792.9
Key Metrics
- Market Cap (In Cr) 10519.08
- Beta 0.55
- Div. Yield (%) 1.87
- P/B 2.01
- TTM P/E 56.31
- Peg Ratio 0.61
- Sector P/E 30.05
- D/E -
- Open Price 535.25
- Prev Close 535.25
Analysis
Price Analysis
-
1 Week-0.64%
-
3 Months-18.5%
-
6 Month-20.44%
-
YTD-6.59%
-
1 Year-29.73%
Risk Meter
- 23% Low risk
- 23% Moderate risk
- 23% Balanced Risk
- 23% High risk
- 23% Extreme risk
Recos
18 Analysts
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Analysts' Views
- Ratings
- Current
- Strong Sell
- 3
- Sell
- 1
- Hold
- 8
- Buy
- 5
- Strong Buy
- 1
Alembic Pharmaceuticals News
Stocks to Watch: RIL, HDFC, Maruti, Wipro, Yes Bank, Tata Motors, Adani group
3 min read . 02 May 2022
Alembic Pharma: More product approvals for U.S. launches suggest worst is behind
1 min read . 11 Jan 2022
Markets likely to be volatile; Vodafone, Axis Bank, Tata Motors, L&T in focus
2 min read . 26 Jul 2021
Pharma market growth declines sequentially in June, but nevertheless impresses
1 min read . 08 Jul 2021Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2022
- Total Revenue
- 5305.79
- Selling/ General/ Admin Expenses Total
- 1945.86
- Depreciation/ Amortization
- 286.78
- Other Operating Expenses Total
- 12.67
- Total Operating Expense
- 4718.33
- Operating Income
- 587.46
- Net Income Before Taxes
- 620.11
- Net Income
- 520.93
- Diluted Normalized EPS
- 26.48
- Period
- 2022
- Total Assets
- 7122.03
- Total Liabilities
- 1884.48
- Total Equity
- 5237.55
- Tangible Book Valueper Share Common Eq
- 258.58
- Period
- 2022
- Cashfrom Operating Activities
- 552.35
- Cashfrom Investing Activities
- -371.97
- Cashfrom Financing Activities
- -217.35
- Net Changein Cash
- -36.97
- Period
- 2021
- Total Revenue
- 5393.13
- Selling/ General/ Admin Expenses Total
- 1745.86
- Depreciation/ Amortization
- 183.47
- Other Operating Expenses Total
- 8.41
- Total Operating Expense
- 4096.3
- Operating Income
- 1296.83
- Net Income Before Taxes
- 1368.08
- Net Income
- 1146.5
- Diluted Normalized EPS
- 59.12
- Period
- 2021
- Total Assets
- 6708.98
- Total Liabilities
- 1642.01
- Total Equity
- 5066.97
- Tangible Book Valueper Share Common Eq
- 241.31
- Period
- 2021
- Cashfrom Operating Activities
- 1463.38
- Cashfrom Investing Activities
- -838.81
- Cashfrom Financing Activities
- -597.43
- Net Changein Cash
- 26.21
- Period
- 2020
- Total Revenue
- 4605.75
- Selling/ General/ Admin Expenses Total
- 1432.08
- Depreciation/ Amortization
- 157.32
- Other Operating Expenses Total
- 27.44
- Total Operating Expense
- 3592.13
- Operating Income
- 1013.62
- Net Income Before Taxes
- 999.82
- Net Income
- 828.81
- Diluted Normalized EPS
- 48.07
- Period
- 2020
- Total Assets
- 5989.05
- Total Liabilities
- 2769.64
- Total Equity
- 3219.41
- Tangible Book Valueper Share Common Eq
- 154.91
- Period
- 2020
- Cashfrom Operating Activities
- 449.13
- Cashfrom Investing Activities
- -731.63
- Cashfrom Financing Activities
- 154.85
- Net Changein Cash
- -127.24
- Period
- 2019
- Total Revenue
- 3934.68
- Selling/ General/ Admin Expenses Total
- 1407.55
- Depreciation/ Amortization
- 115.23
- Other Operating Expenses Total
- 18.87
- Total Operating Expense
- 3193.78
- Operating Income
- 740.9
- Net Income Before Taxes
- 749.32
- Net Income
- 584.37
- Diluted Normalized EPS
- 30.97
- Period
- 2019
- Total Assets
- 4777.76
- Total Liabilities
- 2058.93
- Total Equity
- 2718.83
- Tangible Book Valueper Share Common Eq
- 129.91
- Period
- 2019
- Cashfrom Operating Activities
- 811.96
- Cashfrom Investing Activities
- -755.6
- Cashfrom Financing Activities
- 59.04
- Net Changein Cash
- 115.33
- Period
- 2018
- Total Revenue
- 3130.81
- Selling/ General/ Admin Expenses Total
- 1057.58
- Depreciation/ Amortization
- 105.46
- Other Operating Expenses Total
- 14.72
- Total Operating Expense
- 2620.98
- Operating Income
- 509.83
- Net Income Before Taxes
- 541.27
- Net Income
- 412.64
- Diluted Normalized EPS
- 21.7
- Period
- 2018
- Total Assets
- 3941.05
- Total Liabilities
- 1720.91
- Total Equity
- 2220.14
- Tangible Book Valueper Share Common Eq
- 108.98
- Period
- 2018
- Cashfrom Operating Activities
- 312.41
- Cashfrom Investing Activities
- -884.38
- Cashfrom Financing Activities
- 502.63
- Net Changein Cash
- -69.34
- Period
- 2017
- Total Revenue
- 3134.61
- Selling/ General/ Admin Expenses Total
- 1047.49
- Depreciation/ Amortization
- 82.97
- Other Operating Expenses Total
- 14.95
- Total Operating Expense
- 2596.74
- Operating Income
- 537.87
- Net Income Before Taxes
- 529.09
- Net Income
- 403.16
- Diluted Normalized EPS
- 21.39
- Period
- 2017
- Total Assets
- 2689.26
- Total Liabilities
- 786.93
- Total Equity
- 1902.33
- Tangible Book Valueper Share Common Eq
- 99.48
- Period
- 2017
- Cashfrom Operating Activities
- 328.55
- Cashfrom Investing Activities
- -485.91
- Cashfrom Financing Activities
- -128.88
- Net Changein Cash
- -286.24
- Period
- 2022-12-31
- Total Revenue
- 1509.02
- Selling/ General/ Admin Expenses Total
- 291.36
- Depreciation/ Amortization
- 66.51
- Other Operating Expenses Total
- 513.89
- Total Operating Expense
- 1326.77
- Operating Income
- 182.25
- Net Income Before Taxes
- 168.09
- Net Income
- 121.93
- Diluted Normalized EPS
- 6.2
- Period
- 2022-12-31
- Period
- 2022-12-31
- Period
- 2022-09-30
- Total Revenue
- 1475.01
- Selling/ General/ Admin Expenses Total
- 289.79
- Depreciation/ Amortization
- 67.7
- Other Operating Expenses Total
- 509.45
- Total Operating Expense
- 1309.97
- Operating Income
- 165.04
- Net Income Before Taxes
- 152.96
- Net Income
- 133.35
- Diluted Normalized EPS
- 6.78
- Period
- 2022-09-30
- Total Assets
- 7098.67
- Total Liabilities
- 1978.8
- Total Equity
- 5119.87
- Tangible Book Valueper Share Common Eq
- 259.23
- Period
- 2022-09-30
- Cashfrom Operating Activities
- 414.25
- Cashfrom Investing Activities
- -240.96
- Cashfrom Financing Activities
- -168.98
- Net Changein Cash
- 4.31
- Period
- 2022-06-30
- Total Revenue
- 1262.14
- Selling/ General/ Admin Expenses Total
- 290.41
- Depreciation/ Amortization
- 67.1
- Other Operating Expenses Total
- 578.82
- Total Operating Expense
- 1314.59
- Operating Income
- -52.45
- Net Income Before Taxes
- -60.16
- Net Income
- -65.88
- Diluted Normalized EPS
- -3.35
- Period
- 2022-06-30
- Period
- 2022-06-30
- Period
- 2022-03-31
- Total Revenue
- 1415.74
- Selling/ General/ Admin Expenses Total
- 277.16
- Depreciation/ Amortization
- 123.09
- Other Operating Expenses Total
- 627.45
- Total Operating Expense
- 1413.47
- Operating Income
- 2.27
- Net Income Before Taxes
- 40.6
- Net Income
- 10.71
- Diluted Normalized EPS
- 0.54
- Period
- 2022-03-31
- Total Assets
- 7122.03
- Total Liabilities
- 1884.48
- Total Equity
- 5237.55
- Tangible Book Valueper Share Common Eq
- 258.58
- Period
- 2022-03-31
- Cashfrom Operating Activities
- 552.35
- Cashfrom Investing Activities
- -371.97
- Cashfrom Financing Activities
- -217.35
- Net Changein Cash
- -36.97
- Period
- 2021-12-31
- Total Revenue
- 1271.7
- Selling/ General/ Admin Expenses Total
- 272.78
- Depreciation/ Amortization
- 55.94
- Other Operating Expenses Total
- 400.6
- Total Operating Expense
- 1071.99
- Operating Income
- 199.71
- Net Income Before Taxes
- 196.73
- Net Income
- 176.42
- Diluted Normalized EPS
- 8.98
- Period
- 2021-12-31
- Period
- 2021-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Technical
Moving Average
SMA
- 5 Day538.17
- 10 Day543.92
- 20 Day550.36
- 50 Day572.99
- 100 Day587.54
- 300 Day652.56
Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Sanofi India
- 5300
- -58.55
- -1.09
- 7404.27
- 5350
- 12329.67
- Glenmark Pharmaceuticals
- 399.2
- 13.4
- 3.47
- 512.7
- 348.9
- 10886.05
- Alembic Pharmaceuticals
- 527.95
- -7.3
- -1.36
- 792.3
- 525.3
- 10519.08
- Natco Pharma
- 529.2
- 1
- 0.19
- 936.5
- 502
- 9617.11
- Eris Lifesciences
- 624.95
- -0.55
- -0.09
- 749.85
- 600.5
- 8502.14
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Sanofi India
- 21.55
- 5.54
- 23.41
- 17.92
- Glenmark Pharmaceuticals
- 9.67
- 1.2
- 14
- 8.4
- Alembic Pharmaceuticals
- 20.21
- 2.01
- 20.8
- 15.4
- Natco Pharma
- 71.66
- 2.26
- 13.85
- 23.59
- Eris Lifesciences
- 20.72
- 4.45
- 26.83
- 30.04
Shareholding
- Category
- Percentage
- No. of shares
- Public Shareholding
- 30.39%
- 59,734,871
- Others
- 8.3%
- 16,316,485
- Life Insurance Corporation of India
- 4.33%
- 8,502,500
- Others
- 2.26%
- 4,469,566
- DSP Mutual Fund
- 3.61%
- 7,091,278
- Kotak Mutual Fund
- 1.71%
- 3,369,047
- Others
- 0.54%
- 1,071,786
- Nomura Singapore Limited ODI
- 1.11%
- 2,175,467
- Others
- 3.88%
- 7,623,504
- Others
- 1.26%
- 2,482,490
- Others
- 0.91%
- 1,790,882
- Others
- 0.7%
- 1,384,251
- Others
- 0.67%
- 1,311,903
- Others
- 0.42%
- 824,442
- HUF
- 0.3%
- 588,584
- Unclaimed or Suspense or Escrow Account
- 0.04%
- 76,895
- LLP
- 0.02%
- 36,771
- Director or Director's Relatives
- 0.01%
- 27,034
- Clearing Members
- 0%
- 9,353
- Trusts
- 0%
- 7,350
- Others
- 0.25%
- 500,563
- Others
- 0.04%
- 70,000
- Foreign Bank
- 0%
- 3,250
- Others
- 0%
- 1,470
- Promoter & Promoter Group Shareholding
- 69.61%
- 136,828,253
- Nirayu Limited
- 35.63%
- 70,035,435
- Alembic Limited
- 28.54%
- 56,097,544
- Gallup Trust (Pranav Chirayu Amin)
- 0.05%
- 100,100
- Viramya Packlight LLP
- 0%
- 900
- Paushak Limited
- 0%
- 855
- Laburnum Family Trust (Chirayu Ramanbhai Amin)
- 0%
- 200
- Virsad Family Trust (Pranav Chirayu Amin)
- 0%
- 200
- Alembic City Limited
- 0%
- 100
- CRA Family Trust (Chirayu Ramanbhai Amin)
- 0%
- 100
- Satori Trust (Chirayu Ramanbhai Amin)
- 0%
- 100
- Grace Star Trust (Shaunak Chirayu Amin)
- 0%
- 100
- Shreno Limited
- 0%
- 100
- Shreno Engineering Limited
- 0%
- 100
- Laksh Trust (Chirayu Ramanbhai Amin)
- 0%
- 100
- Shreno Publications Limited
- 0%
- 100
- Chirayu Ramanbhai Amin
- 2.16%
- 4,242,529
- Malika Chirayu Amin
- 1.53%
- 3,005,730
- Pranav Chirayu Amin
- 0.51%
- 1,009,800
- Shaunak Chirayu Amin
- 0.51%
- 1,006,980
- Inaaya Shaunak Amin
- 0.04%
- 80,000
- Naintara Shaunak Amin
- 0.04%
- 80,000
- Barkha Pranav Amin
- 0.03%
- 50,100
- Krupa Shaunak Amin
- 0.03%
- 50,100
- Samira Pranav Amin
- 0.02%
- 30,000
- Ranvir Pranav Amin
- 0.02%
- 30,000
- Udit Chirayu Amin
- 0.51%
- 1,006,980
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 01-Feb-23
- Quarterly Results
- 11-Nov-22
- Quarterly Results
- 04-Aug-22
- Quarterly Results & Others
- 02-May-22
- Audited Results & Dividend
- 10-Feb-22
- Quarterly Results
- 10-Nov-21
- Quarterly Results
- 26-Jul-21
- Quarterly Results
- 04-May-21
- Audited Results & Dividend
- 19-Jan-21
- Quarterly Results
- Meeting Date
- Announced on
- Purpose
- 30-Sept-22
- 02-May-22
- AGM
- 14-Jun-22
- 10-May-22
- COM
- 19-Mar-22
- 11-Feb-22
- POM
- 27-Jul-21
- 15-Jun-21
- AGM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 02-May-22
- 18-Aug-22
- 17-Aug-22
- 10
- 02-May-22
- -
- -
- 10
- 04-May-21
- -
- 19-Jul-21
- 14
No recent bonus announcements.
No recent splits available.
No recent rights issue declared.
Company Profile
ABOUT Alembic Pharmaceuticals
- Industry Biotechnology & Drugs
- ISIN INE901L01018
- BSE Code 533573
- NSE Code APLLTD
Alembic Pharmaceuticals Limited is an India-based pharmaceutical company. The Company is engaged in the active pharmaceutical ingredient (API) business and real estate business. Its pharmaceuticals business is engaged in manufacturing and marketing of fermentation and chemistry-based API. The Company is also engaged in research and development activity at Vadodara. The Company’s real estate business is engaged in the construction of residential and commercial real estate projects and project management and marketing consultancy. Its API manufacturing includes estolate, biphenyl valine oxalate, and venlafaxine. Its residential projects include Samsara, Veda, Shangri La, Urban Forest, Veda II, and KIARA. The Company is also engaged power generation through co-generation plants of approximately 11 megawatts. It has approximately four windmills of total five megawatts. The API manufacturing facility is located at Alembic Road, Vadodara, Gujarat. Its subsidiary is Alembic City Limited.
MANAGEMENT
- Chirayu Amin Executive Chairman of the Board, Chief Executive Officer
- Raj Baheti Chief Financial Officer, Director - Finance, Executive Director
- Charandeep Saluja Company Secretary, Compliance Officer
- Manisha Saraf Compliance Officer, Company Secretary
- Pranav Amin Managing Director, Executive Director
- Shaunak Amin Managing Director, Executive Director
Company Summary
ALEMBIC PHARMACEUTICALS SUMMARY
Alembic Pharmaceuticals is trading 1.36% lower at Rs 527.95 as compared to its last closing price. Alembic Pharmaceuticals has been trading in the price range of 535.45 & 527.3. Alembic Pharmaceuticals has given -6.59% in this year & -0.64% in the last 5 days.
Alembic Pharmaceuticals has TTM P/E ratio 56.31 as compared to the sector P/E of 30.05. There are 18 analysts who have initiated coverage on Alembic Pharmaceuticals. There are 1 analysts who have given it a strong buy rating & 5 analysts have given it a buy rating. 1 analysts have given the stock a sell rating.
The company posted a net profit of 121.93 Crores in its last quarter.
Listed peers of Alembic Pharmaceuticals include Sanofi India (-1.09%), Glenmark Pharmaceuticals (3.47%), Alembic Pharmaceuticals (-1.36%) etc.
Alembic Pharmaceuticals has a 69.61% promoter holding & 30.39% public holding.
FAQs about Alembic Pharmaceuticals
Alembic Pharmaceuticals is trading at 527.95 as on 6 Feb, 2023 3:53:56 PM. This is -1.36% lower as compared to its previous closing price of 535.25
The market capitalization of Alembic Pharmaceuticals is 10519.08 Cr as on 6 Feb, 2023 3:53:56 PM.
The average broker rating on Alembic Pharmaceuticals is Hold. The breakup of analyst rating is given below -
- 3 analysts have given a strong sell rating
- 1 analysts have given a sell rating
- 8 analysts have given a hold rating
- 5 analysts have given a buy rating
- 1 analysts have given a strong buy rating
The 52 wk high for Alembic Pharmaceuticals is 792.3 whereas the 52 wk low is 525.3
Alembic Pharmaceuticals can be analyzed on the following key metrics -
- TTM P/E: 56.31
- Sector P/E: 30.05
- Dividend Yield: 1.87%
- D/E ratio: -
Alembic Pharmaceuticals reported a net profit of 520.93 Cr in 2022.
